Ravish I R, Nerli R B, Amarkhed S S
Department of Urology, KLES Kidney Foundation, Belgaum, India.
Arch Androl. 2007 Jan-Feb;53(1):17-20. doi: 10.1080/01485010600888953.
Patients with lower urinary tract symptoms and enlarged prostate were randomized to receive, in a double blind fashion, either Finasteride 5 mg/day or Dutasteride 0.5 mg/day for a period of 12 weeks. IPSS score, Qmax, and Quality of Life were assessed at the end of 0 and 12 week periods. Dutasteride significantly improved Qmax, reduced IPSS score, and improved Quality of Life as compared to Finasteride at the end of the 12-week period. Dutasteride with its inhibitory effects on type 1 and 2 5alpha-reductase, produces significantly better results than Finasteride.
下尿路症状且前列腺肿大的患者被随机分组，以双盲方式接受为期12周的每日5毫克非那雄胺或每日0.5毫克度他雄胺治疗。在0周和12周结束时评估国际前列腺症状评分（IPSS）、最大尿流率（Qmax）和生活质量。在12周结束时，与非那雄胺相比，度他雄胺显著改善了Qmax，降低了IPSS评分，并改善了生活质量。度他雄胺对1型和2型5α-还原酶具有抑制作用，其效果明显优于非那雄胺。
